Barfresh Announces Second Quarter 2025 Results GlobeNewswire August 13, 2025 Revenue Increased 11% Year-Over-Year to $1.6 Million for Second Quarter 2025 Achieved Gross Margin of 31% for Second Quarter 2025 New Co-Manufacturer Completes Equipment Installation at End of Second Quarter 2025 and Commences Increased Supply for Third Quarter 2025 Company Expects an Increase in Revenue […]
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update GlobeNewswire August 13, 2025 KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of
The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance GlobeNewswire August 13, 2025 CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 13, 2025 Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug.
Coherent Corp. Reports Fourth Quarter and Full Year Fiscal 2025 Results GlobeNewswire August 13, 2025 FY25 REVENUE OF $5.81B, INCREASED 23% Y/Y FY25 GAAP GROSS MARGIN OF 35.2%, INCREASED 424 bps Y/Y; FY25 NON-GAAP GROSS MARGIN OF 37.9%, INCREASED 358 bps Y/Y FY25 GAAP LOSS OF $0.52, IMPROVED $1.32 Y/Y; FY25 NON-GAAP EPS OF $3.53,
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. GlobeNewswire August 13, 2025 CARSON CITY, Nev., Aug.
Noodles & Company Announces Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 BROOMFIELD, Colo., Aug. 13, 2025 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today announced financial results for its second quarter ended July 1, 2025. Key highlights for the second quarter of 2025 versus the second quarter of 2024 include: Total revenue
HeartCore Reports Financial Results for Second Quarter and Six Months Ended June 30, 2025 GlobeNewswire August 13, 2025 NEW YORK and TOKYO, Aug. 13, 2025 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the second quarter
Roadzen Reports Best Fiscal Q1 in Company History with 22% Revenue Growth, 92% Lower Net Loss, and 50% Adjusted EBITDA Improvement Over the Same Quarter Last Year GlobeNewswire August 13, 2025 1. Record Fiscal Q1 Revenue Sets Stage for the Year AheadFirst quarter fiscal 2026 revenue increased 22% to $10.9 million from $8.9 million last
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire August 13, 2025 – Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance – – Exceptional 94% overall survival (OS) observed at